Protalix BioTherapeutics, Inc. (DE) (PLX) Covered Calls

Protalix BioTherapeutics, Inc. operate as biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellExtm protein.

You can sell covered calls on Protalix BioTherapeutics, Inc. (DE) to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PLX (prices last updated Fri 4:16 PM ET):

Protalix BioTherapeutics, Inc. (DE) (PLX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.85 -0.09 2.83 2.89 795K 74 0.2
Covered Calls For Protalix BioTherapeutics, Inc. (DE) (PLX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 16 2.5 0.35 2.54 -1.6% -26.5%
Jun 20 2.5 0.25 2.64 -5.3% -33.9%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Its drug candidates also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. The company was founded on November 30, 1995 and is headquartered in Carmiel, Israel.